Diabetes News

Glomerular hyperfiltration may increase CVD risks, including myocardial infarction and heart failure, for patients with type 2 diabetes, study data show.

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, according to data from a cohort study published in the Journal of Diabetes and Its Complications.

The prevalence of diabetes is increasing faster in some low-income countries than elsewhere in the world, generating concerns about health care infrastructure and access to treatment for people in those regions.

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes.

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated insulin delivery system, according to findings from the SECURE-T2D trial.

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor stroke or transient ischemic attack, a speaker reported.

Genetic risk scores for predicting insulin resistance that were developed for adults are also tied to some cardiometabolic metrics in children and adolescents, according to study findings.

Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required surgical intervention, such as manipulation under anesthesia, according to published results.

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers reported.